Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$48M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$48M
- +22.4% YoY
- EPS (diluted)
- −$0.42
- +25.0% YoY
Source: XBRL data from the ROCKET PHARMACEUTICALS, INC. (RCKT) Q1 2026 10-Q on SEC EDGAR. USD.
ROCKET PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- KRESLADI accelerated FDA approval in March 2026, but no material near-term revenue expected
- PRV sale agreement for $180 million entered in April 2026
- Focus on cardiovascular gene therapy programs, including RP-A501, RP-A601, and BAG3-DCM
- RP-A501 Phase 2 resumed after clinical hold at recalibrated dose of 3.8 × 10¹³ GC/kg
- RP-A501 Phase 2 previously included six treated patients before dosing pause
Risk Factors
- No risk-factors section provided in submitted filing text
- No disclosures indicating newly added or materially changed risks
- No regulatory, legal, compliance, operational, competitive, market, or financial risk details provided
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ROCKET PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.